Biosimilar News: FDA Approves High-concentration, Citrate-free Formulation of Cyltezo, a Biosimilar to Humira
The U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases including psoriasis. “With this FDA approval, we are now able to offer both high- and low-concentration, citrate-free formulations of Cyltezo, further expanding treatment access for patients […]